Jeffrey Hung

Mark Breidenbach

Michael Schmidt

Michael Yee

Swapnil Malekar

Yaron Werber

- Immuneering Corporation entered into an underwriting agreement on **September 24, 2025**, for a public offering of **18,959,914 shares of Class A common stock** at a price of **$9.23 per share**.  **[1790340_0001104659-25-093436_tm2526946d1_8k.htm:1]** **[1790340_0001104659-25-093436_tm2526946d1_ex1-1.htm:17]** **[1790340_0001104659-25-093436_tm2526946d1_ex1-1.htm:33]** 
- The company also granted the underwriters an option to purchase up to an additional **2,843,987 shares** of Class A common stock.  **[1790340_0001104659-25-093436_tm2526946d1_8k.htm:1]** **[1790340_0001104659-25-093436_tm2526946d1_ex1-1.htm:17]** **[1790340_0001104659-25-093436_tm2526946d1_ex1-1.htm:33]** 
- Concurrently, Immuneering Corporation agreed to a private placement with **Aventis Inc.**, a subsidiary of Sanofi, for **2,708,559 shares of Class A common stock** at **$9.23 per share**, totaling **$25.0 million**.  **[1790340_0001104659-25-093436_tm2526946d1_8k.htm:1]** **[1790340_0001104659-25-093436_tm2526946d1_ex1-1.htm:1]** 
- The company expects to receive net proceeds of approximately **$164.1 million** from the public offering and **$23.3 million** from the private placement, which are anticipated to fund its operations **into 2029**.  **[1790340_0001104659-25-093436_tm2526946d1_8k.htm:2]**

Immuneering Corporation Announces Public Offering and Private Placement

- Immuneering Corporation announced a proposed **underwritten public offering** of shares of its Class A common stock or pre-funded warrants to purchase Class A common stock.  **[1790340_0001104659-25-092957_tm2526843d1_ex99-1.htm:0]** 
- Concurrently, Immuneering entered into a private placement agreement with **Sanofi** (through its wholly owned subsidiary Aventis Inc.) for **$25.0 million** of Class A common stock or non-voting Class B common stock.  **[1790340_0001104659-25-092957_tm2526843d1_ex99-1.htm:0]** **[1790340_0001104659-25-092957_tm2526843d1_8k.htm:1]** 
- The private placement is contingent upon the closing of the public offering, which must result in gross proceeds to the company of at least **$75.0 million** and be priced by **September 26, 2025**.  **[1790340_0001104659-25-092957_tm2526843d1_8k.htm:1]** 
- The net proceeds from both the offering and the private placement are intended to advance the preclinical and clinical development of product candidates, and for working capital and other general corporate purposes.  **[1790340_0001104659-25-092957_tm2526843d1_ex99-1.htm:0]** 
- Sanofi's beneficial ownership of Class A Common Stock is initially capped at **4.99%**, with an option to increase this percentage to **9.9%** upon 61 days' notice to the company.  **[1790340_0001104659-25-092957_tm2526843d1_8k.htm:3]** **[1790340_0001104659-25-092957_tm2526843d1_ex10-1.htm:34]**

Immuneering Corporation Announces Proposed Public Offering and Concurrent Private Placement with Sanofi

- Immuneering Corporation announced the closing of a private placement, generating **approximately $25 million** in total up front gross proceeds.  **[1790340_522de32cd0e44b8c8014201439e71bd3_0]** 
- The placement involved the sale of **6,329,113** unregistered shares of Class A common stock (or pre-funded warrants) at a purchase price of **$3.95 per share**.  **[1790340_522de32cd0e44b8c8014201439e71bd3_0]** 
- Accompanying purchase warrants to acquire **2,848,096** shares of Class A common stock were also issued, with an exercise price of **$5.50 per share**.  **[1790340_522de32cd0e44b8c8014201439e71bd3_0]** 
- Immuneering is a **clinical-stage oncology company** focused on developing Deep Cyclic Inhibitors for cancer treatment.  **[1790340_522de32cd0e44b8c8014201439e71bd3_1]**

Immuneering (IMRX)